The first quarter of 2021 sets a new record, but the tide might be starting to turn.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing.
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.